Innovative Solutions to Infectious Diseases
Developing Novel Treatments for Fungal Infections
Our first-in-class antifungal compound utilizes a unique mechanism of action against drug resistant fungi.
Led by Inventors and Industry Experts
Our leaders are pharmaceutical research experts, each with decades of experience.
Combating Drug Resistant Bacterial Infections
Our novel antibiotic is being developed for treatment of antibiotic resistant pathogens such as MRSA.
OCF001: A New Treatment Option for Serious Fungal Infections
For decades, recurrent vulvovaginal candidasis has been a poorly managed disease process treated by a cocktail of ineffective treatments indicated for non-recurrent infections. Thanks to years of groundbreaking research, our lead asset is poised to provide a first-in-class solution to not only this disease, but also to systemic fungal infections in immunocompromised patients.
LAN001: Providing Solutions to Antibiotic Resistance in Bacteria
Prevalence of antibiotic resistant bacteria has been increasing at the same time as the rate of antibiotic discovery has been declining. With our second asset we are a part of a resurgence in antibiotic discovery, providing a new solution to systemic bacterial infections, including those caused by MRSA. With this therapeutic compound, we can reduce mortality and morbidity associated with many emerging antibiotic resistant infections.
Sano Chemicals by the Numbers
>100
Combined Years of Experience
$7.2
Million dollars raised
6
Indications under development
9
Patents Held
>30
Personnel, Advisors and Directors